Invizyne Technologies (IZTC) Competitors $17.40 +1.49 (+9.37%) Closing price 03:59 PM EasternExtended Trading$17.51 +0.11 (+0.63%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends IZTC vs. NMRA, TSHA, VYGR, ENGN, TVGN, SOPH, ATYR, ITOS, CCCC, and SGMOShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Neumora Therapeutics (NMRA), Taysha Gene Therapies (TSHA), Voyager Therapeutics (VYGR), enGene (ENGN), Tevogen Bio (TVGN), SOPHiA GENETICS (SOPH), Atyr PHARMA (ATYR), iTeos Therapeutics (ITOS), C4 Therapeutics (CCCC), and Sangamo Therapeutics (SGMO). These companies are all part of the "biological products, except diagnostic" industry. Invizyne Technologies vs. Neumora Therapeutics Taysha Gene Therapies Voyager Therapeutics enGene Tevogen Bio SOPHiA GENETICS Atyr PHARMA iTeos Therapeutics C4 Therapeutics Sangamo Therapeutics Neumora Therapeutics (NASDAQ:NMRA) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment. Is NMRA or IZTC more profitable? Invizyne Technologies' return on equity of 0.00% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -73.63% -68.97% Invizyne Technologies N/A N/A N/A Do analysts prefer NMRA or IZTC? Neumora Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 759.38%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals have more ownership in NMRA or IZTC? 47.7% of Neumora Therapeutics shares are owned by institutional investors. 26.4% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor NMRA or IZTC? In the previous week, Neumora Therapeutics had 3 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for Neumora Therapeutics and 1 mentions for Invizyne Technologies. Invizyne Technologies' average media sentiment score of 0.93 beat Neumora Therapeutics' score of 0.23 indicating that Invizyne Technologies is being referred to more favorably in the news media. Company Overall Sentiment Neumora Therapeutics Neutral Invizyne Technologies Positive Which has preferable valuation & earnings, NMRA or IZTC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$235.93M-$1.87-1.03Invizyne TechnologiesN/AN/AN/AN/AN/A Does the MarketBeat Community favor NMRA or IZTC? Neumora Therapeutics received 25 more outperform votes than Invizyne Technologies when rated by MarketBeat users. CompanyUnderperformOutperformNeumora TherapeuticsOutperform Votes2589.29% Underperform Votes310.71%Invizyne TechnologiesN/AN/A SummaryNeumora Therapeutics beats Invizyne Technologies on 7 of the 10 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$108.75M$3.09B$5.61B$9.12BDividend YieldN/A1.87%5.36%3.98%P/E RatioN/A45.9589.7717.51Price / SalesN/A344.521,229.1083.39Price / CashN/A188.8944.3037.67Price / BookN/A4.145.124.72Net IncomeN/A-$40.99M$117.86M$224.62M7 Day Performance46.34%-0.35%1.84%-0.42%1 Month Performance8.41%1.50%7.95%3.57%1 Year PerformanceN/A-1.90%26.54%19.11% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$17.40+9.4%N/AN/A$108.75MN/A0.00N/ANews CoverageGap DownNMRANeumora Therapeutics4.2261 of 5 stars$2.00-5.7%$16.50+725.0%-87.7%$323.12MN/A-1.07108Short Interest ↓TSHATaysha Gene Therapies4.0269 of 5 stars$1.53+0.7%$6.63+333.0%-6.3%$313.56M$15.45M2.43180Positive NewsVYGRVoyager Therapeutics4.7565 of 5 stars$5.63+0.2%$15.97+183.6%-27.4%$307.57M$250.01M7.93100Analyst ForecastNews CoverageENGNenGene3.0676 of 5 stars$6.77-5.4%$29.78+339.8%-8.4%$299.37MN/A-11.6731Short Interest ↓High Trading VolumeTVGNTevogen Bio3.8197 of 5 stars$1.68+24.4%$4.20+150.0%N/A$294.08MN/A0.0017News CoverageGap DownHigh Trading VolumeSOPHSOPHiA GENETICS2.5859 of 5 stars$4.48+6.7%$7.40+65.2%-18.6%$292.88M$64.49M-4.11520Short Interest ↓Gap DownHigh Trading VolumeATYRAtyr PHARMA2.4615 of 5 stars$3.46-3.6%$19.25+456.4%N/A$290.43M$350,000.00-3.6853Short Interest ↑News CoveragePositive NewsITOSiTeos Therapeutics4.0614 of 5 stars$7.53-1.4%$22.25+195.5%-29.1%$275.07M$12.60M-2.3990Short Interest ↓CCCCC4 Therapeutics2.1145 of 5 stars$3.62-0.3%$10.67+194.7%-43.3%$255.54M$20.76M-2.13150SGMOSangamo Therapeutics3.0074 of 5 stars$1.13-2.6%$5.17+357.2%+153.1%$235.77M$176.23M-1.51480Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Neumora Therapeutics Alternatives Taysha Gene Therapies Alternatives Voyager Therapeutics Alternatives enGene Alternatives Tevogen Bio Alternatives SOPHiA GENETICS Alternatives Atyr PHARMA Alternatives iTeos Therapeutics Alternatives C4 Therapeutics Alternatives Sangamo Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IZTC) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
